

| 카탈로그 번호 | HC359106 |
|---|---|
| 설명 |
Anti-Human CD47 Reference Antibody (AO-176, RUO) (HC359106) is a human monoclonal antibody detecting CD47.
|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG |
| 클론 ID | AO-176 |
| 생물학적 활성 | AO-176 shows EC 50 values of 130 ng/mL (OV90), 390 ng/mL (HCC827), 649 ng/mL (SNU-1), 250 ng/mL (OV10-315), 2700 ng/mL (MDA-MB-231), 390 ng/mL (Jurkat) and 1910 ng/mL (Raji) [1]. AO-176 (10 ug/mL, 24 h) induces death of Jurkat and OV90 cells [1]. AO-176 (0.017-1000 ug/mL) binds negligibly to RBCs and does not cause agglutination of washed human RBCs [1][3]. AO-176 (10-30 ug/mL, 24 h) has no killing effect on normal cell and the activated T cells [1]. AO-176 (0.001-100 ug/mL, 90 min) directly inhibits the binding of SIRPα to CD47 on Jurkat cells with an IC 50 of 0.78 to 0.87 ug/mL [1]. AO-176 (0.01-10 ug/mL, 2 h) promotes the phagocytosis of both Jurkat, Raji, OV90, Detroit 562, and FaDu cells in a concentration-dependent manner [1][2][4]. AO-176 (1-25 mg/kg, i.v., weekly for 4 weeks) significantly suppresses the tumor growth in Raji lymphoma xenograft mice models [1]. AO-176 (10-25 mg/kg, i.p., weekly or 5 times/weeks for 5-6 weeks) significantly suppresses the tumor growth in MDA-MB-23, SNU-1 and OV90 xenograft mice models [1]. AO-176 (3-25 mg/kg) exerts anti-tumor activity in RPMI-8226 and NCI-H929 xenografted mice models [3][4]. . |
| 타겟 | Antigenic surface determinant protein OA3, CD47, IAP, Integrin-associated protein, Leukocyte surface antigen CD47, MER6, Protein MER6 |
| 내독소 수준 | < 10 EU/mg as determined by LAL method. |
| 순도 | >95% as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | Q08722 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | AO-176, AO176, AO176 |
| 배경 | Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical). 1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 11509594 2. Piccio, L. et al. (2005) Blood 105, 2421-7. PMID: 15383453 3. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 19004835 4. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 7691831 5. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 8550562 6. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621 7. Ghimire, K. et al. (2020) Cells 9. PMID: 32679764 |
| 참고 문헌 | 1. Puro RJ, et al. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846. [HC359106] 2. Andrejeva G, et al. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J Immunol. 2021 Feb 15;206(4):712-721. [HC359106] 3. William Casey Wilson, et al. AO-176, a Highly Differentiated Clinical Stage AntiCD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics. Blood (2020) 136 (Supplement 1): 3–4 [HC359106] 4. John Richards, et al.. Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination. Blood (2019) 134 (Supplement_1): 1844. View More [HC359106] |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CD47/MER6 (AO-176)


빠른 접근
문의하기
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206

中文
English
한국어
日本語
Español
Français
Русский